Raredon, Micha Sam Brickman
Yang, Junchen
Garritano, James
Wang, Meng
Kushnir, Dan
Schupp, Jonas Christian
Adams, Taylor S.
Greaney, Allison M.
Leiby, Katherine L.
Kaminski, Naftali
Kluger, Yuval
Levchenko, Andre
Niklason, Laura E.
Funding for this research was provided by:
National Institutes of Health (F30HL143906, T32GM007205, T32GM007205, U01HL145567, R01GM131642, U54CA209992, 1R01HL138540)
U.S. Department of Defense (W81XWH-19-1-0131)
Article History
Received: 21 September 2021
Accepted: 28 February 2022
First Online: 9 March 2022
Competing interests
: LEN is a founder and shareholder in Humacyte, Inc, which is a regenerative medicine company. Humacyte produces engineered blood vessels from allogeneic smooth muscle cells for vascular surgery. LEN’s spouse has equity in Humacyte, and LEN serves on Humacyte’s Board of Directors. LEN is an inventor on patents that are licensed to Humacyte and that produce royalties for LEN. LEN has received an unrestricted research gift to support research in her laboratory at Yale. Humacyte did not influence the conduct, description or interpretation of the findings in this report. NK reports personal fees from Boehringer Ingelheim, Third Rock, Pliant, Samumed, NuMedii, Indalo, Theravance, LifeMax, Three Lake Partners, RohBar in the last 36 months, and Equity in Pliant. NK is also a recipient of a grant from Veracyte and non-financial support from Miragen. In addition, NK has patents on New Therapies in Pulmonary Fibrosis and ARDS (unlicensed) and Peripheral Blood Gene Expression as biomarkers in IPF (licensed to biotech). None of those are related to the research reported in this manuscript. MSBR does not declare competing interests. JY does not declare competing interests. JG does not declare competing interests. MW does not declare competing interests. DK does not declare competing interests. JCS does not declare competing interests. TSA does not declare competing interests. AMG does not declare competing interests. KLL does not declare competing interests. YK does not declare competing interests. AL does not declare competing interests.